Cutiss AG, a biotechnology firm based in Schlieren in the canton of Zurich, has investigated the efficacy and safety of its skin replacement product denovoSkin as part of two studies. According to a press release, successful results were achieved in the clinical Phase 2 study for denovoSkin in adult and adolescent burns patients. Efficacy has been demonstrated for the personalized dermo-epidermal skin substitute for patients in need of a skin graft after suffering severe burns.
The full data analysis with the three-year follow-up will be available in 2025 and will include the last patient transplant in August 2022.
Cutiss writes in the press release that the five-year follow-up period for the Phase 1 clinical trial, during which the safety of the product was demonstrated, has now been completed. Children and adolescent patients requiring a skin graft due to burn injuries or reconstructive surgery were enrolled in this study.
Cutiss is proud of the progress made so far and the Cutiss team’s hard work, as Cutiss CEO Daniela Marino states in the press release. Preparations will now focus on the “next regulatory steps to bring this promising treatment to patients suffering from severe burns and skin injuries”, Marino explains further.
In 2022, the European Patent Office issued a patent for tissue transplants in accordance with the personalized therapy developed by Cutiss on the basis of bioengineered human skin tissue. Cutiss was founded in 2017 as a spin-off from the University of Zurich and is headquartered at the Bio-Technopark Schlieren-Zurich. gba